What Is the Treatment of Moderate Acute Pulmonary Histoplasmosis in an Immunocompetent Patient?
Clinical Scenario
Immunocompetent adult or child — no immunocompromising condition — presenting with moderate acute pulmonary histoplasmosis: symptoms such as cough, fever, dyspnea, or chest discomfort significant enough to interfere with normal activities, possibly requiring low-flow supplemental oxygen or hospitalisation.
Management Approach
In immunocompetent patients with this presentation, starting antifungal therapy is not automatic. The treating clinician weighs whether to initiate antifungal treatment or to observe without it, guided by the severity and duration of symptoms and the potential harms of treatment.
Treatment Overview
When antifungal therapy is indicated, a specific oral antifungal agent is the preferred choice — selected, dosed, and monitored according to protocol-defined targets. Full dosing guidance, duration, therapeutic drug monitoring goals, and the decision framework are available in the complete protocol.
References
DOI: 10.1093/cid/ciaf256
- In immunocompetent adults and children presenting with moderate acute pulmonary histoplasmosis, the panel suggests either antifungal treatment or no antifungal treatment, considering the severity and duration of signs/symptoms, as well as potential harms of antifungal treatment (conditional recommendation, very low certainty of evidence).
- Moderate acute pulmonary histoplasmosis — Symptoms (eg, cough, fever, dyspnea, chest discomfort) significant enough to interfere with normal activities; may require low-flow oxygen supplementation or hospitalization.
- When treatment is indicated, itraconazole is preferred.
- A goal trough concentration of itraconazole component >1 mg/L and <3–4 mg/L (as measured by chromatographic assay) is associated with efficacy and a lower risk of toxicity.
View source ↗